Biomarker News and Research

RSS

A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule.

GCC hormone receptor may also help fight obesity

The hormone receptor guanylyl cyclase C (GCC) has been established as a suppressor of colorectal cancer tumors, but new evidence from Thomas Jefferson University suggests it may also help fight one of the country's biggest pandemics: obesity.

26 Aug 2011

MDxHealth first half 2011 commercial revenues increase 19%

MDxHealth SA, a leading molecular diagnostics company in the field of personalized medicine, announced today its 2011 half-year results.

25 Aug 2011

AMT total net loss decreases 7% to € 8.7 million for first half year of 2011

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today reported its results for the first half year of 2011.

25 Aug 2011

Insight into acrolein-induced acute lung injury

Metabolon, Inc., the leader in metabolomics, biomarker discovery and biochemical analysis, announces the publication of "Integrative Metabolome and Transcriptome Profiling Reveals Discordant Energetic Stress Between Mouse Strains with Differential Sensitivity to Acrolein-Induced Acute Lung Injury" in The Molecular Nutrition and Food Research Journal.

24 Aug 2011

CHL completes $18.4-million Series B financing round

Cleveland HeartLab Inc. (CHL), a leading specialty clinical laboratory and disease management company, today announced the completion of an $18.4-million Series B financing round.

23 Aug 2011

A CRADA for prostate disease research

Genomatix Software, the Uniformed Service University of the Health Sciences (USU), and the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) have entered into a Cooperative Research and Development Agreement (CRADA) to extend their collaborative endeavors in prostate disease research.

22 Aug 2011

Risk of depression in formerly depressed people

Depression is increasingly recognized as an illness that strikes repeatedly over the lifespan, creating cycles of relapse and recovery. This sobering knowledge has prompted researchers to search for markers of relapse risk in people who have recovered from depression. A new paper published in Elsevier's Biological Psychiatry suggests that when formerly depressed people experience mild states of sadness, the nature of their brains' response can predict whether or not they will become depressed again.

22 Aug 2011

Brain's reaction to sadness can predict risk of future depression

22 Aug 2011

Clinical trials to evaluate and validate infrastructure of P-medicine consortium

Retrospective and prospective clinical trials will be run to evaluate and validate the infrastructure of the P-medicine consortium, announced a poster at the recent 3rd symposium of the Worldwide Innovative Networking in Personalized Cancer Medicine, held in Paris 6-8 July, 2011.

18 Aug 2011

Inherited genetic links to prostate cancer discovered

Researchers from the U.S. and Sweden have linked five inherited genetic mutations to the development of a particularly aggressive and deadly form of prostate cancer. They suggest that these findings could someday lead to development of an easy-to-administer blood test to screen for such mutations to help physicians assess the long-term risk faced by newly diagnosed prostate cancer patients.

17 Aug 2011

Health Canada grants medical device license to Gen-Probe's PROGENSA PCA3 assay

Gen-Probe announced today that Health Canada has granted the Company a medical device license for the PROGENSA(R) PCA3 assay, a new molecular urine test that helps determine the need for repeat biopsies in men suspected of having prostate cancer.

17 Aug 2011

Researchers identify mesothelin antibody that could detect early-stage ovarian cancer

Using a new approach to developing biomarkers for the very early detection of ovarian cancer, researchers at Rush University Medical Center have identified a molecule in the bloodstream of infertile women that could one day be used to screen for those at high risk for the disease — or even those with early-stage ovarian cancer.

17 Aug 2011

Novel assay can accurately detect prostate cancer than traditional screening

new prostate screening test developed by AnalizaDx, Inc., a Cleveland-based biotech company, and studied by researchers at the Seidman Cancer Center at University Hospitals (UH) Case Medical Center along with colleagues at the Cleveland Clinic, the Veterans Administration Boston Healthcare and the National Cancer Institute, may prove to be a promising new tool in the diagnosis of prostate cancer.

16 Aug 2011

Researchers identify novel sensory pathway that modulates pro-inflammatory cells

New research led by Derya Unutmaz, MD associate professor, the Departments of Pathology, Medicine, and Microbiology at NYU School of Medicine and Mark Sundrud, PhD, of Tempero Pharmaceuticals, Inc., has identified a novel sensory pathway that modulates the potency of Th17 cell responses.

11 Aug 2011

Gastroenterology journal publishes results of Lexicon LX1031 Phase 2 trial in IBS

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that results from the Phase 2 clinical trial of LX1031 in patients with non-constipating irritable bowel syndrome (IBS) were published earlier this week in the August 2011 edition of the journal Gastroenterology.

11 Aug 2011

Biomarker may signal whether common back pain treatment will work

A new study from researchers at the Stanford University School of Medicine has identified a unique protein complex that can be used to predict whether an epidural steroid injection will help relieve pain caused by a herniated disc in the lower spine.

10 Aug 2011

TrovaGene regains ownership of worldwide rights to transrenal technology

TrovaGene, Inc., a developer of transrenal molecular diagnostics, confirmed today that it regained ownership of its worldwide rights and control over its patent estate for transrenal technology for non-invasive prenatal applications and cancer through the termination of a license agreement between TrovaGene and Sequenom, Inc.

10 Aug 2011

NanoString launches nCounter Rat miRNA Expression Assay Kit

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced the availability of the nCounter Rat miRNA Expression Assay Kit for use on its nCounter Analysis System.

From NanoString Technologies 9 Aug 2011

Positive data from Lexicon LX1032 Phase 2 study on carcinoid syndrome

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced positive, top-line proof-of-concept data from its recently completed Phase 2 study in carcinoid syndrome with LX1032, telotristat etiprate. Carcinoid syndrome is a chronic condition caused by neuroendocrine tumors that usually originate from the gastrointestinal tract.

9 Aug 2011

Thomson Reuters, ESMO launch new education portal for oncologists

A unique scientific information and education portal designed to help oncologists keep up to date with the latest research and clinical information in their field has been launched by the European Society for Medical Oncology (ESMO) in partnership with Thomson Reuters, the global information and news organization.

9 Aug 2011